f | { | f | { |
| "author": "", | | "author": "", |
| "author_email": "", | | "author_email": "", |
| "creator_user_id": "0124c449-4279-4839-a7e2-f7ee873dbc7c", | | "creator_user_id": "0124c449-4279-4839-a7e2-f7ee873dbc7c", |
| "groups": [ | | "groups": [ |
| { | | { |
| "description": "Group for publications", | | "description": "Group for publications", |
| "display_name": "Publication", | | "display_name": "Publication", |
| "id": "816c3c41-f871-427d-9e26-fb21e6b3c578", | | "id": "816c3c41-f871-427d-9e26-fb21e6b3c578", |
| "image_display_url": | | "image_display_url": |
| mw/uploads/group/2022-03-17-123757.433896243660articlesquareicon.png", | | mw/uploads/group/2022-03-17-123757.433896243660articlesquareicon.png", |
| "name": "publication", | | "name": "publication", |
| "title": "Publication" | | "title": "Publication" |
| } | | } |
| ], | | ], |
| "id": "392167b0-d865-4262-b070-c0b0e45b721b", | | "id": "392167b0-d865-4262-b070-c0b0e45b721b", |
| "isopen": false, | | "isopen": false, |
| "license_id": "notspecified", | | "license_id": "notspecified", |
| "license_title": "License not specified", | | "license_title": "License not specified", |
| "maintainer": null, | | "maintainer": null, |
| "maintainer_email": null, | | "maintainer_email": null, |
| "metadata_created": "2021-09-16T08:11:53.798306", | | "metadata_created": "2021-09-16T08:11:53.798306", |
n | "metadata_modified": "2022-04-26T13:49:03.814805", | n | "metadata_modified": "2022-04-26T13:52:34.052676", |
| "name": "malawi-integrated-hiv-program-report-2012-q4", | | "name": "malawi-integrated-hiv-program-report-2012-q4", |
| "notes": "This is the sixth quarterly HIV Program report after | | "notes": "This is the sixth quarterly HIV Program report after |
| implementation of the 2011 Integrated Clinical\r\nHIV Guidelines in | | implementation of the 2011 Integrated Clinical\r\nHIV Guidelines in |
| July 2011. A summary of the key achievements between __October and | | July 2011. A summary of the key achievements between __October and |
| December\r\n2012__ is provided below:\r\n\r\n\u2022 Scale-up of | | December\r\n2012__ is provided below:\r\n\r\n\u2022 Scale-up of |
| integrated HIV services had reached the following number of | | integrated HIV services had reached the following number of |
t | sites:\r\n\r\n *__825__static (607 within and 218 outside of health | t | sites:\r\n\r\n __825__static (607 within and 218 outside of health |
| facilities) and 534 outreach HTC sites\r\n\r\n *__651__(static) ART | | facilities) and 534 outreach HTC sites\r\n\r\n __651__(static) ART |
| sites\r\n\r\n __585__PMTCT sites (Option B+)\r\n\r\n __577__ | | sites\r\n\r\n __585__PMTCT sites (Option B+)\r\n\r\n __577__ |
| Pre-ART sites\r\n\r\n __579__ sites with HIV-exposed child | | Pre-ART sites\r\n\r\n __579__ sites with HIV-exposed child |
| follow-up\r\n\r\n\u2022 __378,560__ persons were tested and counselled | | follow-up\r\n\r\n\u2022 __378,560__ persons were tested and counselled |
| for HIV and __33,718 (9%)__ were HIV positive;\r\n__143,906 (38%)__ | | for HIV and __33,718 (9%)__ were HIV positive;\r\n__143,906 (38%)__ |
| people tested for the first time.\r\n\r\n\u2022 __111,503 (68%)__ of | | people tested for the first time.\r\n\r\n\u2022 __111,503 (68%)__ of |
| 163,510 women at ANC had their HIV status ascertained; __9,891 (9%)__ | | 163,510 women at ANC had their HIV status ascertained; __9,891 (9%)__ |
| of\r\nthese were HIV positive. __117,730 (88%)__ of 132,755 women at | | of\r\nthese were HIV positive. __117,730 (88%)__ of 132,755 women at |
| maternity had their HIV status\r\nascertained; __9,647 (8%)__ of these | | maternity had their HIV status\r\nascertained; __9,647 (8%)__ of these |
| were HIV positive.\r\n\r\n\u2022 24,168 patients started ART during | | were HIV positive.\r\n\r\n\u2022 24,168 patients started ART during |
| this quarter; this is a further decrease from the previous\r\nquarter | | this quarter; this is a further decrease from the previous\r\nquarter |
| (26,909). Some of this decline was probably due to a shortage of HIV | | (26,909). Some of this decline was probably due to a shortage of HIV |
| test kits.\r\n\u2022 404,905 patients were alive and on ART by end of | | test kits.\r\n\u2022 404,905 patients were alive and on ART by end of |
| December 2012; 72,612 (19%) of 376,094\r\non first line adult regimens | | December 2012; 72,612 (19%) of 376,094\r\non first line adult regimens |
| were on ART regimen 5A (tenofovir / lamivudine / efavirenz)\r\n\u2022 | | were on ART regimen 5A (tenofovir / lamivudine / efavirenz)\r\n\u2022 |
| 80% of adults and 81% of children were retained alive on ART at 12 | | 80% of adults and 81% of children were retained alive on ART at 12 |
| months after ART\r\ninitiation.\r\n\u2022 A total of 10,882 HIV | | months after ART\r\ninitiation.\r\n\u2022 A total of 10,882 HIV |
| positive pregnant women were on ART: 4,211 (39%) of these | | positive pregnant women were on ART: 4,211 (39%) of these |
| were\r\nalready on ART when getting pregnant and 6,671 (61%) started | | were\r\nalready on ART when getting pregnant and 6,671 (61%) started |
| ART during\r\npregnancy/delivery. 6,349 (95%) of pregnant women | | ART during\r\npregnancy/delivery. 6,349 (95%) of pregnant women |
| started ART due to Option B+ (in WHO\r\nclinical stage 1 or 2) and 322 | | started ART due to Option B+ (in WHO\r\nclinical stage 1 or 2) and 322 |
| (5%) due to a low CD4 count and/or WHO clinical stage 3 or | | (5%) due to a low CD4 count and/or WHO clinical stage 3 or |
| 4.\r\n\u2022 An additional 2,297 breastfeeding women started ART due | | 4.\r\n\u2022 An additional 2,297 breastfeeding women started ART due |
| to Option B+ (in WHO clinical\r\nstage 1 or 2).\r\n\u2022 5,701 (84%) | | to Option B+ (in WHO clinical\r\nstage 1 or 2).\r\n\u2022 5,701 (84%) |
| of 6,815 women started under Option B+ were retained at 6 months after | | of 6,815 women started under Option B+ were retained at 6 months after |
| ART\r\ninitiation (6-month retention outcomes were missing for 1,348 | | ART\r\ninitiation (6-month retention outcomes were missing for 1,348 |
| women registered, mainly at\r\nsites with electronic data | | women registered, mainly at\r\nsites with electronic data |
| systems).\r\n\u2022 9,082 (8%) of infants discharged alive from | | systems).\r\n\u2022 9,082 (8%) of infants discharged alive from |
| maternity were known to be HIV exposed, 8,174\r\n(90%) of these | | maternity were known to be HIV exposed, 8,174\r\n(90%) of these |
| received ARV prophylaxis. 5,397 (59%) were enrolled in exposed child | | received ARV prophylaxis. 5,397 (59%) were enrolled in exposed child |
| followup\r\nbefore age 2 months.\r\n\u2022 A total of 11,156 HIV | | followup\r\nbefore age 2 months.\r\n\u2022 A total of 11,156 HIV |
| exposed children and 8,774 pre-ART patients enrolled for follow-up | | exposed children and 8,774 pre-ART patients enrolled for follow-up |
| in\r\nHIV Care Clinics (HCC) during this quarter.\r\n\u2022 658 health | | in\r\nHIV Care Clinics (HCC) during this quarter.\r\n\u2022 658 health |
| workers were trained in the new integrated PMTCT/ART curriculum during | | workers were trained in the new integrated PMTCT/ART curriculum during |
| Q4\r\n2012, bringing the total number trained in the 2011 guidelines | | Q4\r\n2012, bringing the total number trained in the 2011 guidelines |
| to 5,297. 112 District\r\nPMTCT/ART coordinators were trained in | | to 5,297. 112 District\r\nPMTCT/ART coordinators were trained in |
| developing plans for Elimination of Mother to\r\nChild | | developing plans for Elimination of Mother to\r\nChild |
| Transmission.\r\n\u2022 30 TB Officers in the SE Zone were trained in | | Transmission.\r\n\u2022 30 TB Officers in the SE Zone were trained in |
| ART/TB management.\r\n\u2022 60 HTC Counsellors received training in | | ART/TB management.\r\n\u2022 60 HTC Counsellors received training in |
| collecting dried blood spot specimens for Early\r\nInfant Diagnosis | | collecting dried blood spot specimens for Early\r\nInfant Diagnosis |
| (EID).\r\n\u2022 100 facilities received mentoring for HIV Exposed | | (EID).\r\n\u2022 100 facilities received mentoring for HIV Exposed |
| Child Follow-Up and EID specimen\r\ncollection.\r\n\u2022 598 Health | | Child Follow-Up and EID specimen\r\ncollection.\r\n\u2022 598 Health |
| workers at 92 facilities in the SE Zone and 227 health workers and | | workers at 92 facilities in the SE Zone and 227 health workers and |
| support staff\r\nat 33 facilities in the N Zone received clinical | | support staff\r\nat 33 facilities in the N Zone received clinical |
| mentoring in provision of PMTCT/ART.", | | mentoring in provision of PMTCT/ART.", |
| "num_resources": 1, | | "num_resources": 1, |
| "num_tags": 1, | | "num_tags": 1, |
| "organization": { | | "organization": { |
| "approval_status": "approved", | | "approval_status": "approved", |
| "created": "2021-10-14T11:02:35.234558", | | "created": "2021-10-14T11:02:35.234558", |
| "description": "The Department of HIV & AIDS (DHA) was established | | "description": "The Department of HIV & AIDS (DHA) was established |
| in 2001, initially as a unit in the Department of Clinical Services, | | in 2001, initially as a unit in the Department of Clinical Services, |
| to coordinate the biomedical HIV Program in Malawi. The department now | | to coordinate the biomedical HIV Program in Malawi. The department now |
| carries responsibility for various HIV related programs including: | | carries responsibility for various HIV related programs including: |
| sexually transmitted infections (STIs), prevention of mother to child | | sexually transmitted infections (STIs), prevention of mother to child |
| transmission of HIV (PMTCT), and national voluntary male medical | | transmission of HIV (PMTCT), and national voluntary male medical |
| circumcision program (VMMC). All these HIV program sub-sections are | | circumcision program (VMMC). All these HIV program sub-sections are |
| linked to one robust monitoring and evaluation sub-section in the HIV | | linked to one robust monitoring and evaluation sub-section in the HIV |
| and AIDS Department which technically operates under the Central | | and AIDS Department which technically operates under the Central |
| Monitoring and Evaluation Department (CMED) of the Ministry of | | Monitoring and Evaluation Department (CMED) of the Ministry of |
| Health.", | | Health.", |
| "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | | "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", |
| "image_url": | | "image_url": |
| 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", | | 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", |
| "is_organization": true, | | "is_organization": true, |
| "name": "dha", | | "name": "dha", |
| "state": "active", | | "state": "active", |
| "title": "Department of HIV & AIDS and Viral Hepatitis", | | "title": "Department of HIV & AIDS and Viral Hepatitis", |
| "type": "organization" | | "type": "organization" |
| }, | | }, |
| "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | | "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", |
| "private": false, | | "private": false, |
| "program_area": "Care and Treatment", | | "program_area": "Care and Treatment", |
| "relationships_as_object": [], | | "relationships_as_object": [], |
| "relationships_as_subject": [], | | "relationships_as_subject": [], |
| "resources": [ | | "resources": [ |
| { | | { |
| "cache_last_updated": null, | | "cache_last_updated": null, |
| "cache_url": null, | | "cache_url": null, |
| "created": "2022-03-23T19:55:47.446798", | | "created": "2022-03-23T19:55:47.446798", |
| "description": "", | | "description": "", |
| "format": "PDF", | | "format": "PDF", |
| "hash": "", | | "hash": "", |
| "id": "7f3ba4ca-40c4-4baa-92fe-9317b9945f6f", | | "id": "7f3ba4ca-40c4-4baa-92fe-9317b9945f6f", |
| "last_modified": "2022-04-05T00:56:38.282373", | | "last_modified": "2022-04-05T00:56:38.282373", |
| "lfs_prefix": | | "lfs_prefix": |
| "dha/malawi-integrated-hiv-program-report-2012-q4", | | "dha/malawi-integrated-hiv-program-report-2012-q4", |
| "metadata_modified": "2022-04-05T00:56:38.294202", | | "metadata_modified": "2022-04-05T00:56:38.294202", |
| "mimetype": "application/pdf", | | "mimetype": "application/pdf", |
| "mimetype_inner": null, | | "mimetype_inner": null, |
| "name": "malawi-integrated-hiv-program-report-2012-q4", | | "name": "malawi-integrated-hiv-program-report-2012-q4", |
| "package_id": "392167b0-d865-4262-b070-c0b0e45b721b", | | "package_id": "392167b0-d865-4262-b070-c0b0e45b721b", |
| "position": 0, | | "position": 0, |
| "resource_type": null, | | "resource_type": null, |
| "sha256": | | "sha256": |
| "4e982db7be9e944088e3948624ae30aba42fbe1b62e57baafb8372aa77a3fe8a", | | "4e982db7be9e944088e3948624ae30aba42fbe1b62e57baafb8372aa77a3fe8a", |
| "size": 1853519, | | "size": 1853519, |
| "state": "active", | | "state": "active", |
| "url": | | "url": |
| 17b9945f6f/download/malawi-integrated-hiv-program-report-2012-q4.pdf", | | 17b9945f6f/download/malawi-integrated-hiv-program-report-2012-q4.pdf", |
| "url_type": "upload" | | "url_type": "upload" |
| } | | } |
| ], | | ], |
| "state": "active", | | "state": "active", |
| "tags": [ | | "tags": [ |
| { | | { |
| "display_name": "Report", | | "display_name": "Report", |
| "id": "37e5a5df-a993-4d3f-8c9c-73c418c30f0f", | | "id": "37e5a5df-a993-4d3f-8c9c-73c418c30f0f", |
| "name": "Report", | | "name": "Report", |
| "state": "active", | | "state": "active", |
| "vocabulary_id": null | | "vocabulary_id": null |
| } | | } |
| ], | | ], |
| "title": "Malawi Integrated HIV Program Report 2012 Q4", | | "title": "Malawi Integrated HIV Program Report 2012 Q4", |
| "type": "dataset", | | "type": "dataset", |
| "url": null, | | "url": null, |
| "version": null, | | "version": null, |
| "year": "2012" | | "year": "2012" |
| } | | } |